This study tests a new drug, **Nuvisertib (TP-3654)**, to see if it's safe and helps patients with **myelofibrosis (MF)**, a condition where scar tissue forms in the bone marrow, affecting blood cell production. The study has three groups: one for patients who didn't do well with another treatment called a **JAK inhibitor**, one for patients still taking **ruxolitinib** but not improving, and one for patients previously treated with a JAK inhibitor (but not momelotinib).
To join, you need to have certain blood counts, a good liver and kidney function, and a life expectancy of at least six months. Patients must not have recent surgeries, certain infections, or other health issues.
- Expect regular hospital visits for tests and assessments.
- Potential risks include side effects from the drug.
- Compensation for participation is likely provided.
How understandable was the trial content above?
Hard to understand
Easy to understand